News and Announcements
Proteomics PromarkerD Development Advances in China
- Published June 14, 2016 2:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
14th June 2016, ASX Announcement
Highlights:
- PILL and its Chinese partner Newsummit Biopharma have secured funding towards development for an In vitro Diagnostic (IVD) kit for PromarkerD in China.
- Chinese patent granted for PromarkerD as a predictive and diagnostic test for diabetic kidney disease.
- Initial tranche of funding under the PILL-NSB agreement will support the first stage of PromarkerD IVD kit manufacture.
- China is a key global market for PILL – WHO estimates 120m Chinese have diabetes and are at risk of kidney disease.
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce significant advances towards commercialisation of PromarkerD as an In vitrro Diagnostic (IVD) test in China, with the grant of a key patent and funds secured to initiate kit manufacture.
To view the full announcement, please click on the button below.